SCHEMBL3086016

SCHEMBL3086016

CCN(C(=O)C(Cc1ccc(OCc2ccccc2)cc1)C(=O)O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 4/20 0.54
PPARG P37231 4/20 0.54
PPARD Q03181 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
ALOX5 P09917 3/20 0.52
MAOB P27338 3/20 0.52
NOX1 Q9Y5S8 1/20 0.49
FFAR1 O14842 1/20 0.49
FFAR4 Q5NUL3 1/20 0.49
MME P08473 1/20 0.48
ACE P12821 1/20 0.48
CPA1 P15085 1/20 0.48
ACE2 Q9BYF1 1/20 0.48
LTA4H P09960 1/20 0.48
PTGS1 P23219 1/20 0.48
PTGS2 P35354 1/20 0.48
TSPO P30536 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3092971 0.88 BCHE (0.50) ALOX5MAOBNOX1FFAR1MME
SCHEMBL27787093 0.88 BCHE (0.53) PPARAPPARGPPARDL3MBTL1ALOX5
SCHEMBL3096888 0.81 PPARG (0.45) PPARAPPARGPPARDL3MBTL1ALOX5
SCHEMBL3096879 0.81 PPARG (0.45) PPARAPPARGPPARDL3MBTL1ALOX5
SCHEMBL7801265 0.81 PPARA (0.70) PPARAPPARGPPARDMAOBFFAR1
SCHEMBL3091855 0.81 ALDH1A1 (0.49) PPARAPPARG
SCHEMBL3092117 0.81 ALDH1A1 (0.49) MME
SCHEMBL27787119 0.79 CYP4F2 (0.49) ALOX5MAOBFFAR1MMEACE
SCHEMBL3080460 0.79 TP53 (0.47)
SCHEMBL5702266 0.79 L3MBTL1 (0.63) L3MBTL1ALOX5MAOBNOX1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 PPARA 37/4885PPARG 136/4885PPARD 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.